This company has been marked as potentially delisted and may not be actively trading. Zafgen (ZFGN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ZFGN vs. MBX, NLTX, CYBN, BIOA, VIRI, WHWK, AVTE, PYRGF, OSTX, and ELYMShould you be buying Zafgen stock or one of its competitors? The main competitors of Zafgen include MBX Biosciences (MBX), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Aerovate Therapeutics (AVTE), PyroGenesis Canada (PYRGF), OS Therapies (OSTX), and Eliem Therapeutics (ELYM). Zafgen vs. Its Competitors MBX Biosciences Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics Aerovate Therapeutics PyroGenesis Canada OS Therapies Eliem Therapeutics Zafgen (NASDAQ:ZFGN) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts prefer ZFGN or MBX? MBX Biosciences has a consensus target price of $37.63, indicating a potential upside of 190.54%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Zafgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zafgen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ZFGN or MBX? In the previous week, MBX Biosciences had 4 more articles in the media than Zafgen. MarketBeat recorded 4 mentions for MBX Biosciences and 0 mentions for Zafgen. MBX Biosciences' average media sentiment score of 0.42 beat Zafgen's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Zafgen Neutral MBX Biosciences Neutral Do institutionals and insiders believe in ZFGN or MBX? 70.4% of Zafgen shares are owned by institutional investors. 14.2% of Zafgen shares are owned by insiders. Comparatively, 52.2% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better valuation & earnings, ZFGN or MBX? Zafgen is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZafgenN/AN/A-$45.41M-$1.07-3.48MBX BiosciencesN/AN/AN/A-$4.54-2.85 Is ZFGN or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Zafgen's return on equity.Company Net Margins Return on Equity Return on Assets ZafgenN/A -51.34% -34.55% MBX Biosciences N/A N/A N/A SummaryMBX Biosciences beats Zafgen on 9 of the 11 factors compared between the two stocks. Get Zafgen News Delivered to You Automatically Sign up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZFGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZFGN vs. The Competition Export to ExcelMetricZafgenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.39M$816.03M$5.54B$9.82BDividend YieldN/A4.84%4.62%4.12%P/E Ratio-3.881.2030.0926.02Price / SalesN/A36.57461.38112.87Price / CashN/A19.5637.7558.93Price / Book2.766.588.506.06Net Income-$45.41M-$4.11M$3.26B$265.11M Zafgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZFGNZafgenN/A$3.72+0.5%N/A-51.1%$139.39MN/A-3.8838High Trading VolumeMBXMBX Biosciences2.5551 of 5 stars$12.53+11.3%$37.63+200.3%N/A$418.80MN/A-2.7636News CoverageNLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-43.8%$191.25MN/A-6.5490News CoverageHigh Trading VolumeCYBNCybin1.9791 of 5 stars$7.63+5.1%$85.00+1,014.0%N/A$171.26MN/A-1.7450News CoveragePositive NewsBIOABioAge LabsN/A$4.48+3.2%N/AN/A$155.59M$3.86M0.00N/AAnalyst RevisionVIRIVirios Therapeutics0.0986 of 5 stars$4.77-2.5%$5.00+4.8%+2,598.9%$91.86MN/A-17.675WHWKWhitehawk TherapeuticsN/A$1.71+1.2%N/AN/A$79.65M$25.98M-28.5040Earnings ReportAVTEAerovate TherapeuticsN/A$7.40-1.2%N/A-87.9%$77.68MN/A-2.4720Gap UpHigh Trading VolumePYRGFPyroGenesis CanadaN/A$0.28+4.2%N/A-53.6%$51.78M$9.14M-4.6090Gap DownOSTXOS Therapies2.2897 of 5 stars$1.78+6.6%$18.00+911.2%-41.3%$50.01MN/A-2.07N/AELYMEliem TherapeuticsN/A$1.65-2.9%N/A-74.1%$49.09MN/A-3.119 Related Companies and Tools Related Companies MBX Alternatives NLTX Alternatives CYBN Alternatives BIOA Alternatives VIRI Alternatives WHWK Alternatives AVTE Alternatives PYRGF Alternatives OSTX Alternatives ELYM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZFGN) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zafgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access